1/45
Looks like no tags are added yet.
Selective Estrogen Receptor Modulators (SERMs)
Estrogen receptor ligands that act like estrogens in some tissues but antagonize estrogen action in other tissues
Antagonistic activity is used to treat certain hormone sensitive tumors (e.g., breast cancer)
Tamoxifen AND toremifene antagonist and agonist activity
Estrogen ANTAGONIST on breast tissue (so tx breast cancer)
Estrogen AGONIST on bone, cholesterol metabolism, endometrium, coagulation
system
agonist on Bone - inc bone mineral density
endometrium → endometrial cancer
tamoxifene toxicity and associated monitoring
due to hormonal changes
Hot flashes, mood changes, vaginal bleeding
monitor for abnormal vaginal bleeding/discharge
other
cataracts
thromboembolism (DVT, stroke, PE)
monitor: s/s of VTE
CI: DVT/PE
again: endometrial hyperplasia/cancer
Tamoxifene DI
2D6 inhibitor - dec tamoxifen efficacy
2C9 inhibitor - avoid concurrent use w/ warfarin cuz will lead to excess anticoagulant effect
Tamoxifen 2D6 drug interaction mechanism
what drug to avoid
what is the alternative

Tamoxifen CI
DVT/PE, concurrent warfarin therapy
Toremifene toxicity and asociated monitoring
Unique: QT prolongation
monitor: electrolytes (Mg, K, Ca), ECG/EKG
rest similar to tamoxifene except no cataract
due to hormonal changes
hot flashes, vaginal discharge
monitor: abnormal vaginal bleeding/discharges
other
thromboembolism,
monitor: s/s VTE
endometrial hyperplasia/cancer
toremifene CI
related to QT
congenital/acquired QT prolongation
uncorrected HoK, HoMg
Raloxifene MOA
Estrogen ANTAGONIST on breast tissue and endometrium — NO ENDO cancer
Estrogen AGONIST on bone, cholesterol metabolism, coagulation system
same as other SERM except endometrium is antagonized
Raloxifene toxicity and associated monitoring
Unique: higher DVT/PE, inc risk of death due to stroke
monitor: s/s of VTE
flu-like symptoms,
due to hormone
hot flashes, arthralgia/myalgias (no vaginal discharge)
Raloxifene CI
DVT/PE
Pregnancy (THE ONLY ONE OUT OF 3 CI)
Selective Estrogen Receptor Down regulator (SERD) MOA and indication
MOA: Competitively binds to estrogen receptors (ER) on tumors and other tissue targets, producing a nuclear complex that causes a down-regulation of ERs; this results in inhibition of tumor growth
No estrogenic effects
Drug: fulvestrant
Fulvestrant toxicity and associated monitoring
even though no hormonal changes: Hot flashes, athralgias/myalgias
inc LFTs,
monitor: LFTs
injection site pain, hematoma/bleeding (from injection)
Monitor: s/s of bleeding
Monitor: pregnancy test (rmbr: raloxifene is CI w/ Pregnancy)
Aromatase inhibitor MoA
Aromatase converts androgens (androstenedione and testosterone) to estradiol (estrogen)
Inhibiting aromatase decreases production of estradiol
Can only be used in postmenopausal women
what one is REversible, nonsteroidal; and IRREversible, steroidal AI?
Reversible, non-steroidal
anastrozle
letrozole
IRReversible, steroidal
exemestane

AI class toxicity and it’s monitoring
UNIQUE (extra effect due to hormonal changes):
dec bone mineral density → osteoporosis, fractures (take ca++, vit/D or biphosphonates)
monitor: DEXA scans, serum Ca++, vit D levels
hormonal changes:
Hot flashes, arthralgias/myalgias, sexual dysfunction
other
inc LFTs
monitor: liver function
inc cholesterol
monitor: lipid profile
AI class CI
premenopausal women
pregnancy (rmbr: fulvestrant, raloxifene)
nonsteroidal anti-androgen MOA
first gen
2nd gen
1st generation:
Binds to androgen receptors and competitively blocks testosterone from binding
2nd generation:
In addition to above:
Inhibits androgen receptor nuclear translocation and DNA transcription → apoptosis
common toxicity for nilutamide and bicalutamide and its associated monitoring
hepatotoxicity
monitor: LFTs
loss of glycemic control. bicalutamide is specifically in pt w/ diabetes, nilutamide did not specify
monitor: blood glucose
Nilutamide additional toxicity and its monitoring
UNIQUE: Night blindness (25-40%)
interstitial pnuemontitis
Monitor: chest X-ray
alcohol intolerance
Bicalutamide addtional toxicity and monitoring
Unique: QTC prolongation (rmbr: toremixifene)
monitor: ECG
dec bone density
2nd gen (enzalutamide, apalutamide, darolutamide) class toxicity and its monitoring parameter
Imp: CV events, seizures
monitor: s/s of IHD and seizures
note: doralutamide seizure risk not as high compared to enzalutamide and apalutamide cuz not cross BBB
Due to hormonal
hot flashes, gynecomastia, dec libido, impotence (note: we are in men now)
note: no additional toxicity for Darolutamide
enzalutamide additional toxicity and its monitoring parameter
fractures
Monitoring parameter unrelated to toxicity
CBC
LFT
BP
Apalutamide additional toxicity and its monitoring parameter
Unique: dermatologic toxicity, QTC (rmbr Bicalutamide, toremifene)
monitor: dermatologic toxicity, EKG/ECG
Hypothyroidism
Monitor: TSH
Fracture (was also in enzalutamide)
2nd gen Androgen antagonist drug interaction
enzalutamide
apalutamide
darolutamide
All 3 → CYP3A4 substrate
Enza + Apa → Strong 3A4 inducer, 2C19 inducer
Enza + Apa → CYP2C8 substrate
enza only: 2c9 inducer
Daro → P-gp substrate
steroial anti -androgen (abiraterone) MOA
Selectively and irreversibly inhibits CYP17
Inhibits formation of testosterone precursors– dehydroepiandrosterone (DHEA) and androstenedione
dec DHT, dec cortisol, inc aldosterone
Abiraterone → Blocks CYP17 → ↓ Cortisol → ↑ ACTH → ↑ Mineralocorticoids (aka adrenal insufficiency)
that is why you co-administer steroid to prevent inc ACTH

Abirasterone must be given with:
steroid: prednisone or methylprednisolone
abiraterone PK: absorption and DDI
Absorption:
Zytiga® only: empty stomach.: Taking with food causes unpredictable absorption that may be as high as 10x if taken without food.
Substrate of CYP3A4 – drug-drug interactions with inhibitors or inducers
abiraterone toxicity and monitoring
Unique: adrenal insufficiency and compensatory mineralocorticoid excess (hoK, Joint swelling/edema, HTN) - MUST BE CO-administered w/ corticosteroid
monitor: s/s of Adrenal insufficiency, electrolyte, fluid status, BP
Hepatotoxicity (rmbr 1st gen: nil and bicalutamide)
monitor: LFT
Hot flashes
GnRH normal physiology

GnRH receptor agonist and antagonists MOA
GnRH antagonist onset is faster than GnRH agonist


Just read, no back
Tumor flare in prostate cancer w/ GnRH AGONist
can lead to various symptoms and even oncologic emergencies
if worry, use GnRH antagonist

GnRH agonist and antagonist class toxicity and shared AE and monitor
dec bone mineral density, osteoporosis - Ca++ and Vit D supplement
monitor: bone mineral density (get a baseline)
Metabolic Effect
hyperglycemia (new-onset diabetes),
Monitor: blood glucose
CAD, MI, QTC prolongation (rmbr apalutamide, Bicalutamide, toremifene)
monitor: ECG/EKG
Other due to hormonal
hot flashes, dec libido, emotional lability/depression
Tumor flare: only with AGONist
monitor: spinal cord compression, urinary tract obstruction
GnRH agonist female and male additional specific toxicity
GnRH antagonist male ONLY toxicity — not used in Female
Female: vaginal dryness, amenorrhea
Male: impotence, gynecomastia
Proteasome inhibitor MOA
general
Bortezomib
carfilzomib
Both lead to cell cycle arrest and apoptosis
Bortezomib: Reversibly inhibit 26S proteosome
Carfilzomib: IRReversibly inhibit 20S proteosome (proteolytic core w/in the 26S proteosome)

bortezomib and carfilzomib shared AE and monitoring
supportive care
myelosuppression
Monitor: CBC
hepatotoxicity
Monitor: LFTs (dose adjustment)
herpes reactivation
SUPPORTIVE care: Antiviral prophylaxis
Bortezomib addtional toxicity and monitoring
Uniue: peripheral neuropathy (SQ <<< IV)
monitor: signs of peripheral neuropathy
Carfilzomib toxicity and monitoring
Unique:
CV events (HF, Pulmonary Edema, MI)
Infusion-related rxn
renal toxicity
Monitor: BP, s/s of infusion-related rxn, SCr
IMiD toxicity
Unique: Teratogenicity (REM), Thromboembolism, 2nd meliganancy
monitor: pregnancy test, s/s VTE
VTE so severe that need VTE prophylaxis for supportive care
myelosuppression, Heptotoxicity
Monitor: CBC, LFT
Peripheral neuropathy (thalidomide » lenalidomide/pomalidomide)
dermatologic rxn
which IMiD has DDI (only 1)?
pomalidomide - 1A2
smoking may induce metabolism and dec efficacy

Just read, no back
no back

Just read
no back
Asparaginase (Pegaspargase) product MOA

Pagaspargase toxicity and its monitoring parameter
unique:
coagulopathies (hemorrhage and thrombosis) - VTE prophylaxis can be used if platelet count is adequate but need close monitoring)
monitor: coagulation parameter, S/S VTE
Pancreatitis
monitor: amlyase/lipase
HyperTGC, hyperglycemia
monitor: TGC, blood glucose
hypersensitivity - cutaneous rxn, edema, hoTN, SOB, respiratory collapse
hepatotoxicity
monitor: LFT
Pegaspargase supportive care
